Oral GLP-1 Agonist Buffering System for Enzyme Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral administration methods for GLP-1 receptor agonists are limited by sensitivity to digestive enzymes, leading to rapid degradation and inefficacy, necessitating parenteral administration which is less comfortable and less compliant for patients.
Innovation Solution
A pharmaceutical composition comprising a GLP-1 receptor agonist combined with a pH buffering system that maintains a pH range of 4 to 8, effectively protecting the agonist from degradation by digestive enzymes such as pepsin, thereby enhancing stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If GLP-1 receptor agonist is administered orally, then patient compliance and comfort are improved, but the agonist is degraded by digestive enzymes such as pepsin
Solution Approach 1:
The patent introduces pepsin inhibitors as intermediary substances that mediate between the orally administered GLP-1 receptor agonist and the harmful digestive enzyme pepsin. The pepsin inhibitor acts as a protective intermediary that neutralizes pepsin's degradative effect while allowing the agonist to remain accessible for absorption, thus enabling oral administration without sacrificing stability.
Solution Approach 2:
The patent extracts or removes the harmful element (pepsin activity) from the gastrointestinal environment by introducing specific inhibitors that selectively neutralize pepsin without affecting other digestive processes or the therapeutic action of the GLP-1 receptor agonist. This extraction of the harmful enzymatic activity allows the agonist to survive oral administration.
2Reliability
If GLP-1 receptor agonist is administered parenterally, then agonist stability is improved, but patient compliance and comfort deteriorate
Solution Approach 1:
The pepsin inhibitor serves as a protective intermediary that enables the agonist to withstand the oral route by neutralizing digestive enzymes in the gastrointestinal tract, thereby providing an alternative to parenteral administration while maintaining agonist stability through chemical protection rather than route change.
3Reliability
If GLP-1 receptor agonist is protected from pepsin degradation, then agonist stability is improved, but protection against other digestive enzymes such as trypsin may be insufficient
Solution Approach 1:
The patent employs a buffering system with pH range of 4-8 that provides universal protection against multiple types of digestive enzymes (pepsin, trypsin, and others) by maintaining optimal pH conditions that inhibit broad-spectrum enzymatic activity, rather than relying on specific inhibitors for each enzyme type.
Solution Approach 2:
The formulation combines multiple protective components including pepsin inhibitors, buffering agents, and excipients to create a composite protective system that addresses degradation from various digestive enzymes simultaneously, providing comprehensive protection throughout the gastrointestinal tract.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The buffering system provides at least 70% protection of the GLP-1 receptor agonist from degradation, allowing for effective oral administration and maintaining biological activity, as demonstrated by structural and functional analyses.
Implementation Method 1
a system that can buffer the pH of the pharmaceutical composition to a value ranging from 4 to 8
Data Source
AI summary
The invention relates to a pharmaceutical composition for use as a medicament, in the oral treatment of a disease, in particular a metabolic disease, said pharmaceutical composition comprising a Glucagon-like peptide-1 receptor agonist (GLP-1), and a system that can buffer the pH of the pharmaceutical composition to a value ranging from 4 to 8.